MAPK8 and acute respiratory distress syndrome: Studies have shown that p38MAPK specific inhibitor SB203580 and JNK selective inhibitor SP600125 can reduce the inflammatory cytokine release in BALF, improve the pulmonary histology, and reduce the mortality rate of LPS-induced ALI [8, 28].